INXN 3001
Alternative Names: DC-IL-12; DC-RTS-IL12; IL-12 DNA; INcell-1001; ZIN-CTI-001Latest Information Update: 05 Apr 2023
Price :
$50 *
At a glance
- Originator Intrexon Corporation
- Developer Precigen Inc
- Class Antineoplastics; Cell therapies; Gene therapies
- Mechanism of Action Gene transference; Interleukin-12 expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Malignant melanoma